Clinical significance of the rivaroxaban–dronedarone interaction: insights from physiologically based pharmacokinetic modelling

por Hügl, Burkhard, Horlitz, Marc, Fischer, Kerstin, Kreutz, Reinhold
Publicado 2023

Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential

por Willmann, Stefan, Coboeken, Katrin, Kapsa, Stefanie, Thelen, Kirstin, Mundhenke, Markus, Fischer, Kerstin, Hügl, Burkhard, Mück, Wolfgang
Publicado 2021

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation

por Cappato, Riccardo, Marchlinski, Francis E., Hohnloser, Stefan H., Naccarelli, Gerald V., Xiang, Jim, Wilber, David J., Ma, Chang-Sheng, Hess, Susanne, Wells, Darryl S., Juang, George, Vijgen, Johan, Hügl, Burkhard J., Balasubramaniam, Richard, De Chillou, Christian, Davies, D. Wyn, Fields, L. Eugene, Natale, Andrea
Publicado 2015